Xenon Pharma Anticipates Several Milestones In Partnered Programs

(RTTNews) - Xenon Pharmaceuticals Inc. (XENE), Thursday said it expects significant progress in 2015 as its partnered clinical-stage programs are moving toward achieving near-term milestones. The company said its Extreme Genetics discovery platform has enabled to generate an attractive and diverse portfolio of assets with significant therapeutic and commercial potential.

According to Xenon, it leverage the potential of its discovery platform to identify novel genes and to exploit expertise in ion channel chemistry and biology to generate an expanded portfolio of product candidates.

Xenon's partner Teva Pharmaceutical Industries Ltd. (TEVA) has randomized 300 patients in its phase 2 trial of TV - 45070 in osteoarthritis and will initiate a Phase 2b clinical trial for TV-45070 in postherpetic neuralgia in the first half of 2015. Roche Group, another partner is currently conducting a Phase 1 clinical trial for GDC-0276, which is expected to be completed by mid-2015. Xenon and Genentech formed a second collaboration in 2014 focused on pain genetics and rare phenotypes to identify new pain targets for drug discovery in 2015. Xenon said it expects Glybera to be launched in Europe in the first quarter of 2015.